StockTipsArenaBeta

BUY AstraZeneca Pharma India Ltd. — Laxmikant Shukla, YES Securities

BUYAstraZeneca Pharma India Ltd.
AstraZeneca Pharma India share price target & all analyst calls

byLaxmikant Shukla, YES SecuritiesHorizon: NA (inferred Swing (≤2wk))26 May 2026via ET Now

Entry₹8,950Stated
Target₹9,700
Total upside +8.38% (call closed)
Stop loss₹8,480-5.25% risk
Exit—No position was opened
ExpiredNA
Follow Laxmikant Shukla for new calls(29% target hit, 113 closed calls)Get alertsWatch ASTRAZEN for new buy/sell callsGet alertsSee 151 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 8:28 pm IST
1 supporting1 neutral1 opposing
Supports the BUY call (1)

AstraZeneca Pharma India announced consistent 33% growth for FY 2025-2026 in its annual results press release.

NSE · Press Release·26 May · 2w ago

(opens in new tab)
Neutral / worth noting (1)

AstraZeneca Pharma India Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company also recommended a dividend of Rs. 36 per equity share, su

NSE · Outcome of Board Meeting·26 May · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

AstraZeneca Pharma India Ltd. received an appeal order from the Deputy Commissioner of State Tax (Appeal) for FY 2018-19, upholding certain adjustments related to supplies under the Patient Access Pro

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·4 Jun · 5d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on AstraZeneca Pharma India

All analyst calls on AstraZeneca Pharma India

More from Laxmikant Shukla, YES Securities

Every call and its outcome